{"id":701490,"date":"2022-10-26T22:44:05","date_gmt":"2022-10-27T02:44:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/"},"modified":"2022-10-26T22:44:05","modified_gmt":"2022-10-27T02:44:05","slug":"lost-money-in-y-mabs-therapeutics-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/","title":{"rendered":"Lost Money in Y-mAbs Therapeutics, Inc.?"},"content":{"rendered":"

<\/p>\n

Lost Money in Y-mAbs Therapeutics, Inc.?<\/b><\/p>\n

Gibbs Law Group Investigates Potential Securities Law Violations<\/b><\/p>\n

OAKLAND, Calif.–(BUSINESS WIRE<\/a>)–
\nShares of Y-mAbs Therapeutics, Inc. dropped 27% on October 26, 2022 after the FDA posted briefing documents regarding the company\u2019s neuroblastoma drug, omburtamab, stating there were \u201csignificant questions” as to the adequacy and control of the submitted study. Previously, in October of 2020, the FDA had issued a Refusal to File letter for omburtamab. Gibbs Law Group is looking into a potential Y-mAbs Therapeutics (YMAB) Securities Class Action Lawsuit<\/a> on behalf of shareholders who lost money in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB).\n<\/p>\n

To speak with an attorney regarding this class action lawsuit investigation, <\/b>click here<\/b><\/a> or <\/b>call (888) 410-2925.<\/b><\/p>\n

\nOn Wednesday, October 26, 2022, shares of cancer pharmaceutical company Y-mAbs Therapeutics, Inc. dropped after the FDA posted briefing documents regarding the company\u2019s neuroblastoma drug, omburtamab, stating there were \u201csignificant questions as to whether the submitted study can be considered an adequate and well-controlled trial necessary to establish effectiveness.\u201d\n<\/p>\n

\nPreviously, in y-mAbs\u2019s earnings call for Q2 of 2022 on August 9, 2022, the company assured investors it had been involved in a number of \u201congoing\u201d discussions with the FDA regarding omburtamab and the team was \u201cconfident\u201d they would be able to address any issues raised. The company further expressed, \u201cgiven the fact that [neuroblastoma] is a rare disease, in an area of unmet medical need with very poor prognosis, we also believe the FDA\u2026will look at this as an area where flexibility needs to be applied in making any judgments around risk benefit assessments.\u201d\n<\/p>\n

\nThis is not the first set-back Y-mAbs has received for its drug omburtamab. In October of 2020, the FDA had issued a Refusal to File letter, leading Y-mAbs to resubmit its application for the drug on April 1, 2022.\n<\/p>\n

\nFollowing this news of the FDA\u2019s concerns, y-mAbs\u2019s stock price dropped 23% on October 26, 2022, causing significant harm to investors.\n<\/p>\n

What Should Y-mAbs Investors Do?<\/b><\/p>\n

\nIf you invested in Y-mAbs, visit our website<\/a> or contact our securities team directly at (888) 410-2925 <\/b>to discuss how you may be able to recover your losses. Our investigation concerns whether y-mAbs Therapeutics, Inc. has violated federal securities laws by providing false or misleading statements to investors.\n<\/p>\n

About Gibbs Law Group<\/b><\/p>\n

\nGibbs Law Group represents investors throughout the country in securities litigation<\/a> to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the world\u2019s largest corporations, and our attorneys have received numerous honors for their work, including \u201cBest Lawyers in America,\u201d \u201cTop Plaintiff Lawyers in California,\u201d \u201cCalifornia Lawyer Attorney of the Year,\u201d \u201cClass Action Practice Group of the Year,\u201d \u201cConsumer Protection MVP,\u201d and \u201cTop Women Lawyers in California.\u201d\n<\/p>\n

This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20221026006163\/en\/<\/a><\/span><\/p>\n

\nEILEEN EPSTEIN
\n
PHONE: 510.350.9728
\n
EMAIL: EJE@CLASSLAWGROUP.COM<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Lost Money in Y-mAbs Therapeutics, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations OAKLAND, Calif.–(BUSINESS WIRE)– Shares of Y-mAbs Therapeutics, Inc. dropped 27% on October 26, 2022 after the FDA posted briefing documents regarding the company\u2019s neuroblastoma drug, omburtamab, stating there were \u201csignificant questions” as to the adequacy and control of the submitted study. Previously, in October of 2020, the FDA had issued a Refusal to File letter for omburtamab. Gibbs Law Group is looking into a potential Y-mAbs Therapeutics (YMAB) Securities Class Action Lawsuit on behalf of shareholders who lost money in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB). To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925. On Wednesday, October 26, 2022, … <\/p>\n

Continue reading “Lost Money in Y-mAbs Therapeutics, Inc.?”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701490","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLost Money in Y-mAbs Therapeutics, Inc.? - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lost Money in Y-mAbs Therapeutics, Inc.? - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lost Money in Y-mAbs Therapeutics, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations OAKLAND, Calif.–(BUSINESS WIRE)– Shares of Y-mAbs Therapeutics, Inc. dropped 27% on October 26, 2022 after the FDA posted briefing documents regarding the company\u2019s neuroblastoma drug, omburtamab, stating there were \u201csignificant questions” as to the adequacy and control of the submitted study. Previously, in October of 2020, the FDA had issued a Refusal to File letter for omburtamab. Gibbs Law Group is looking into a potential Y-mAbs Therapeutics (YMAB) Securities Class Action Lawsuit on behalf of shareholders who lost money in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB). To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925. On Wednesday, October 26, 2022, … Continue reading "Lost Money in Y-mAbs Therapeutics, Inc.?"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T02:44:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221026006163r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lost Money in Y-mAbs Therapeutics, Inc.?\",\"datePublished\":\"2022-10-27T02:44:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/\"},\"wordCount\":513,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221026006163r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/\",\"name\":\"Lost Money in Y-mAbs Therapeutics, Inc.? - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221026006163r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2022-10-27T02:44:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221026006163r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221026006163r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lost-money-in-y-mabs-therapeutics-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lost Money in Y-mAbs Therapeutics, Inc.?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lost Money in Y-mAbs Therapeutics, Inc.? - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/","og_locale":"en_US","og_type":"article","og_title":"Lost Money in Y-mAbs Therapeutics, Inc.? - Market Newsdesk","og_description":"Lost Money in Y-mAbs Therapeutics, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations OAKLAND, Calif.–(BUSINESS WIRE)– Shares of Y-mAbs Therapeutics, Inc. dropped 27% on October 26, 2022 after the FDA posted briefing documents regarding the company\u2019s neuroblastoma drug, omburtamab, stating there were \u201csignificant questions” as to the adequacy and control of the submitted study. Previously, in October of 2020, the FDA had issued a Refusal to File letter for omburtamab. Gibbs Law Group is looking into a potential Y-mAbs Therapeutics (YMAB) Securities Class Action Lawsuit on behalf of shareholders who lost money in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB). To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925. On Wednesday, October 26, 2022, … Continue reading \"Lost Money in Y-mAbs Therapeutics, Inc.?\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T02:44:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221026006163r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lost Money in Y-mAbs Therapeutics, Inc.?","datePublished":"2022-10-27T02:44:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/"},"wordCount":513,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221026006163r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/","name":"Lost Money in Y-mAbs Therapeutics, Inc.? - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221026006163r1&sid=flmnd&distro=nx&lang=en","datePublished":"2022-10-27T02:44:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221026006163r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221026006163r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lost-money-in-y-mabs-therapeutics-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lost Money in Y-mAbs Therapeutics, Inc.?"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701490"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701490\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}